Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Collaboration revenue:
Collaboration revenue from customers	[1]	$ 0	$ 0	$ 330,531
Total collaboration revenue		0	0	330,531
Operating expenses:
Research and development expense	[2]	418,778	396,440	423,876
General and administration		136,564	105,438	103,354
Total operating expenses		555,342	501,878	527,230
Gain from divestiture of small molecule programs		0	14,537	0
Loss from operations		(555,342)	(487,341)	(196,699)
Interest and other income, net		42,904	64,636	51,505
Loss before income taxes		(512,438)	(422,705)	(145,194)
Income tax expense		(102)	(68)	(30)
Net loss		(512,540)	(422,773)	(145,224)
Other comprehensive income (loss):
Net unrealized gain (loss) on marketable securities, net of tax		(1,338)	1,377	7,529
Comprehensive loss		$ (513,878)	$ (421,396)	$ (137,695)
Net loss per share, basic (usd per share)		$ (2.97)	$ (2.57)	$ (1.06)
Net loss per share, diluted (usd per share)		$ (2.97)	$ (2.57)	$ (1.06)
Weighted average number of shares outstanding, basic (in shares)		172,649,097	164,473,772	137,370,897
Weighted average number of shares outstanding, diluted (in shares)		172,649,097	164,473,772	137,370,897

[1] Includes related-party collaboration revenue from customers of $295.5 million for the year ended December 31, 2023.

[2] Includes expense for cost sharing payments to a related party of $17.7 million for the year ended December 31, 2023.